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Interferon-induced protein of (IP-10) inhibits tumor
progression. Tumor cells can produce interferon-in-
duced protein of IP-10 in response to interferon-g. His-
tamine in the vicinity of tumor cells may sustain the
tumor progression. We examined the in vitro e¡ects of
histamine on interferon-induced protein of IP-10 pro-
duction in human squamous cell carcinoma and mela-
noma. Histamine suppressed interferon-g-mediated
interferon-induced protein of IP-10 secretion and
mRNA expression in SV40-transformed keratinocytes,
SCC15, SCC4, and melanoma WM115, WM266-4, and
C32. Histamine suppressed interferon-g-induced inter-
feron-mediated protein of IP-10 promoter activa-
tion in these cells, and the interferon-stimulated
response element on the promoter was responsible for
the suppression. Histamine suppressed interferon-g-
mediated transcription through the interferon-sti-
mulated response element and signal transducer and
activator of transcription 1a binding to the interferon-sti-
mulated response element. Histamine suppressed inter-
feron-g-induced tyrosine phosphorylation of the signal
transducer and activator of transcription 1a, Janus tyro-
sine kinase 1, and Janus tyrosine kinase 2. Histamine-
mediated suppression on the interferon-g-induced
interferon-mediated protein of IP-10 synthesis was
counteracted by the H2 receptor antagonist cimetidine,
adenylate cyclase inhibitor SQ22536, and protein kinase
A inhibitor H-89, but were not a¡ected by H1 receptor
antagonist mepyramine. Cimetidine, SQ22536, and
H-89 also counteracted histamine-mediated suppres-
sion on the interferon-g-induced transcription through
the interferon-stimulated response element, signal
transducer and activator of transcription 1a binding to
the interferon-stimulated response element, and tyro-
sine phosphorylation of the signal transducer and acti-
vator of transcription 1a, Janus tyrosine kinase 1, and
Janus tyrosine kinase 2. Histamine increased intracellu-
lar 30,50 -adenosine cyclic monophosphate level and pro-
tein kinase A activity in squamous cell carcinoma and
melanoma, and the e¡ects of histamine were blocked
by cimetidine. These results suggest that histamine
may interact with H2 receptor on squamous cell carci-
noma and melanoma and generate 30,50 -adenosine
cyclic monophosphate, which may activate protein
kinase A. The cyclic 30,50 -adenosine monophosphate/
protein kinase A signaling pathway induced by hista-
mine may inhibit interferon-g-induced signal transdu-
cer and activator of transcription 1a activation and
suppress interferon-induced protein of IP-10 synthesis.
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I
t is reported that mast cells are accumulated and their de-
granulation is often seen in the vicinity of skin cancer, such
as squamous cell carcinoma (SCC) or melanoma (Claudatus
et al, 1986; Danner and Luger, 1987; Woolley et al, 1988;
Khare et al, 1998). These phenomena may be caused by the
cancer-derived cytokines or chemical mediators inducing mast
cell migration, proliferation, di¡erentiation, or degranulation,
such as interleukin (IL)-3 or substance P (Danner and Luger,
1987 Khare et al, 1998). Histamine is one of the major components
released from mast cells by degranulation, and is assumed to
modulate tumor progression (Tilly et al, 1990; Khare et al, 1998).
Certain melanoma cells also express histidine decarboxylase, the
enzyme converting L-histidine to histamine, and release hista-
mine (Haak-Frendscho et al, 2000; Hegyesi et al, 2001). Four kinds
of histamine receptors have been identi¢ed, H1, H2, H3, and H4
receptors (Oda et al, 2000). It is reported that histamine enhances
the growth of and motility of epidermoid carcinoma and mela-
noma via H1 or H2 receptors (Tilly et al, 1990; Falus et al, 2001).
Histamine also inhibits: (i) cell-mediated anti-tumor immune
responses in tumor hosts (Uotila, 1996); (ii) IL-12, IL-1b, or
tumor necrosis factor-a production in monocyte/macrophages
(Elenkov et al, 1998); (iii) IL-2 and interferon (IFN)-g production
in T cells and natural killer cells (Arad et al, 1996); and (iv)
the cytotoxic activity of natural killer cells via the H2 receptor
(Uotila, 1996).
IFN-induced protein of 10 kDa (IP-10) chemoattracts activated
T helper (Th)1 cells, and induces anti-tumor immune responses
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in synergy with IL-12 (Narvaiza et al, 2000). It is reported that
tumor cells can produce IP-10 in response to IFN-g (Bukowski
et al, 1999). IP-10 expressed by tumor cells assists in the homing
of tumor-suppressive lymphocytes into the tumor tissues (Nar-
vaiza et al, 2000). Though IP-10 preferentially attracts activated
CD4þ Th1 cells, activated Th1 cells stimulate natural killer cells
or macrophages to kill tumor cells or stimulate dendritic cells to
prime cytotoxic T cells (Hung et al, 1998; Lanzavecchia, 1998).
Thus IP-10 contributes to tumor killing e¡ects via activated Th1
cells. In addition, IP-10 inhibits tumor angiogenesis and abrogates
the route for nutrition and metastasis (Arenberg et al, 1996). The
induction of IP-10 production in tumor cells is thus greatly useful
for the therapy of malignant tumors. As histamine inhibits the
production of tumor-suppressive cytokines or chemokines, it is
hypothesized that histamine released from tumor cells or peritu-
moral mast cells may inhibit IP-10 production in tumor cells, and
thus sustain the growth and survival of tumor cells.
In this study, we investigated the e¡ects of histamine on IFN-
g-induced IP-10 production in human skin cancers, SCC and
melanomas.We found the suppressive e¡ects of histamine on IP-
10 transcription via H2 receptors.We further analyzed the precise
mechanisms for the suppression, focusing on the e¡ects of hista-
mine on the IFN-g-activated transcription factor, signal transdu-
cer and activator of transcription (STAT) 1a.
MATERIALS AND METHODS
Reagents Histamine dihydrochloride, imetit dihydrobromide, cimeti-
dine, mepyramine, and calphostin C were obtained from Sigma (St Louis
MO). Dimaprit hydrochloride, thioperamide maleate, and 6-[2-(4-
imidazolyl)ethylamino]-N-(tri£uoromethylphenyl)heptanecarboxamide
dimaleate (HTMT) were from Biomol Research Laboratories Inc.
(Plymouth Meeting, PA). 9-(tetrahydro-20 -£uryl)adenine (SQ22536), 1-
[6-((17b-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl]-1H-pyrrole-
2,5-dione (U73122), and N-[[2-(p-bromocinnamylamino)ethyl]-5-
isoquinolinesulfonamide (H-89), forskolin, and dibutyryl cyclic 30,50 -
adenosine monophosphate (cAMP) were obtained from Calbiochem (La
Jolla, CA). Recombinant human IFN-g AND IFN-a were purchased
from R&D (Minneapolis, MN). Antibodies against phosphotyrosine
(PY20), STAT1a p91, 48 kDa IFN-stimulated response element (ISRE)-
binding protein (p48), Janus tyrosine kinase (Jak) 1, and Jak2 were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell lines Primary melanomaWM115, its metastatic derivativeWM266-
4, and amelanotic melanoma C32 were purchased from Dainippon
Pharmaceutical (Osaka, Japan), and were cultured in Dulbecco modi¢ed
Eagle’s medium (Gibco-BRL, Grand Island, NY) supplemented with 10%
fetal bovine serum (Gibco-BRL), 1% nonessential amino acids, 1 mM
sodium pyruvate (ICN Biomedicals Inc., Aurora, OH), and antibiotics.
SCC4 and SCC15 were purchased from American Type Culture
Collection (Rockville, MD), and were maintained in 1:1 mixture of
Dulbecco modi¢ed Eagle’s medium and Ham’s F12 supplemented with
10% fetal bovine serum and 0.4 mg per ml hydrocortisone. SV40-
transformed keratinocyte cell line was established from human neonatal
foreskin keratinocytes as described (Miquel et al, 1996) and cultured in a
3 :1 mixture of Dulbecco modi¢ed Eagle’s medium and Ham’s F12 with
10% fetal bovine serum, 0.4 mg hydrocortisone per ml, and 10 ng
epidermal growth factor per ml. The order of di¡erentiation capacity was
SV40-transformed keratinocytes4SCC154SCC4, as judged by epithelial
strati¢cation at the air^liquid interface (Lechner and Laimins, 1991).
Measurement of IP-10 secretion SCC, SV40-transformed
keratinocytes, or melanoma cells (4104 per well) were seeded in
triplicate into 24-well plates in 1ml culture medium, adhered overnight,
then the medium was changed to serum and growth factor-free medium,
and incubated for 24 h. The medium was removed and the cells were
preincubated with histamine for 10min, then incubated with IFN-g for
another 24 h. The supernatants were assayed for IP-10 by enzyme-linked
immunosorbent assay (ELISA) (HyCult Biotechnology, b.v.; Uden,
Netherlands). The sensitivity of the assay was 20 pg per ml.
Reverse transcription^polymerase chain reaction (reverse trans-
cription^PCR) SCC or melanoma cells were incubated as above
for 3 h, and total cellular RNA was extracted using mRNA puri¢cation
kit (Pharmacia, Uppsala, Sweden) according to the manufacturer’s
instructions. cDNA was made from RNA samples as described
(Tjandrawinata et al, 1997). Primers for ampli¢cation and the sizes
of respective PCR products were as follows: H1 receptor 50 -
TGGTCACAGTAGGGCTCAAC-30 and 50 -CAAGGTGGGACAGGTA-
GAAGT-30 for 497 bp; H2 receptor, 50 -TCGTGTCCTTGGCTATCAC-30
and 50 -CCTTGCTGGTCTCGTTCCT-30 for 330 bp; H3 receptor, 50 -
CTCCTCTGCCTTCAACATCG-30 and 50 -GGTATGTGCGACGACTA-
CTA-30 for 779 bp; H4 receptor, 50 -CATTGTCCTCATCAGCTATGATC-
30 and 50 -AGCGCTTGTGACACAATGGATAC-30 for 782 bp; IP-10, 50 -
TGACTCTAAGTGGCATTCAAGG-30 and 50 -GATTCAGACATCTCTT-
CTCACCC-30 for 188 bp; glyceraldehyde-3-phosphate dehydrogenase 50 -
GCAGGGGGGAGCCAAAAGGG-30 and 50 -TGCCAGCCCCAGCGTC-
AAAG-30 for 566 bp (Heuer et al, 1996; Jansen-Olesen et al, 1997; Boorsma
et al, 1998; Nakamura et al, 2000;Wang et al, 2000). PCRwas performed by
one denaturing cycle of 951C for 3min, 35 cycles of denaturation at 951C
for 30 s, annealing at 581C for 30 s, and extension at 721C for 30 s, and a
¢nal extension at 721C for 3min. The PCR products were analyzed by
electrophoresis on 2.5% agarose gels and stained with ethidium bromide,
viewed by ultraviolet light. Densitometric analysis was performed by
scanning the bands into Photoshop and performing densitometry with
NIH Image Software.
Competitive reverse transcription^PCR for IP-10 The expression of
IP-10 mRNA was quanti¢ed by competitive reverse transcription^PCR,
where the PCR reactions included not only the cDNA of the sample but
also serial dilutions of a competitor. The PCR competitor for IP-10 was
generated by performing a PCR reaction facilitating mismatch priming
between the primers for IP-10 and human genomic DNA from peripheral
blood mononuclear cells as described (Igaz et al, 1998). To facilitate
mismatch priming, the annealing temperature for PCR was lowered to
431C. The resulting products were run on 2.5% agarose gel, and a band
with a size (295 bp) di¡erent from that of the original IP-10 PCR product
was selected, puri¢ed, and cloned by blunt end ligation in Escherichia coli
D5a. The competitive PCR reactions were performed by adding the same
amount of cDNA to the reaction mixture and altering the amount of a
competitor in a 2-fold dilution concentration series. The PCR program
applied was the same as that for the regular IP-10 reverse transcription^
PCR. The zone of equivalence, where the intensity of the band of IP-10
was equal to that of the competitor, indicated the amount of IP-10
expression.
Plasmids and transfections The ¢re£y luciferase reporter plasmids
driven by human IP-10 promoter (^525/þ 97 bp relative to the
transcriptional start site) were constructed by PCR and insertion into
pGL3 basic vector (Promega, Madison,WI) as described (Majumder et al,
1998). Site-speci¢c mutation of the promoter was created by multiple
rounds of PCR using primers with altered bases as described (Ohmori
and Hamilton, 1993). p3xISRE-SV-luc was constructed by inserting three
copies of ISRE (50 -CGCTTTGGAAAGTGAAACCTACCTC-30,
consensus sequence underlined) from human IP-10 promoter in front of
heterologous minimal SV40 promoter upstream of ¢re£y luciferase
reporter as described (Ohmori and Hamilton, 1993; Ohmori et al, 1994).
Transient transfections were performed using Lipofectamine Plus reagent
(Gibco/BRL, Grand island, NY) according to the manufacturer’s
protocol. Brie£y, tumor cells were plated in six-well plates and grown to
about 80% con£uence, then serum and growth factor deprived for 24 h.
The cells were incubated with 1.8 mg of luciferase construct and 0.2mg of
Rous sarcoma virus b-galactosidase vector per well in the mixture of
medium, Plus reagent, and lipofectamine for 5 h, and were washed and
incubated in serum and growth factor-free medium for 18 h. Cells were
washed, and pretreated with several reagents for 10min, then treated with
histamine for 10min prior to the addition of IFN-g. After 6 h, luciferase
activities of the cell extracts were quanti¢ed using the luciferase assay
system (Promega). The same extracts were assayed for b-galactosidase
activity using chemiluminescent Galacto-Light kit (Tropix, Bedford,
MA). The results obtained in each transfection were normalized for
b-galactosidase activity and expressed as relative luciferase activity.
Electrophoretic mobility shift assay The probe used was annealed
double-stranded DNA containing ISRE from human IP-10 promoter.
The probe was labeled by [32P]deoxycytidine triphosphate. For gel shift
assays, 2^5 mg of nuclear protein extracts were incubated at room
temperature for 5min with a mixture containing 6 mM HEPES (pH 7.9),
0.4 mM ethylenediamine tetraacetic acid, 125 mM KCl, 10% glycerol, 0.05 mg
poly dI-dC per ml, 1 mM dithiothreitol, 2.5 mM sodium pyrophosphate, 1
mM b-glycerophosphate, 1 mM Na3VO4, 10 mM NaF, 50 mg aprotinin per
ml, and 50 mg leupeptin per ml. One nanogram of labeled probe was
added and the reactions were incubated for another 20min. In antibody
supershift experiments, the nuclear extracts were preincubated with
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various antibodies for 30min before the addition of the probe. Reactions
were then fractionated on a nondenaturing 5% polyacrylamide gel, and
visualized with phosphorimager (Molecular Dynamics, Sunnyvale, CA).
Analysis of STAT1a and Jak1/2 phosphorylation The phos-
phorylation of Jak1/Jak2 and STAT1a was assessed by immuno-
precipitation followed by immunoblotting as described (Delgado and
Ganea, 2000). Cells were lyzed and STAT1a, Jak1, and Jak2molecules in
the lysates were immunoprecipitated by 10 mg per ml of respective
antibodies, and were captured on protein G-Sepharose beads (Pharmacia,
Piscataway, NJ). Precipitated proteins were released from the beads,
and were separated by sodium dodecyl sulfate^polyacrylamide gel
electrophoresis on a 10% acrylamide-resolving gel, and transferred to a
nitrocellulose membrane. The membrane was blocked, and incubated
with 1 mg anti-phosphotyrosine antibody (PY20) per ml, washed, and
incubated with horseradish peroxidase-conjugated goat anti-mouse
IgG (Amersham, Arlington Heights, IL) and washed. The blots were
developed with an enhanced chemiluminescence kit (Amersham).
Following analysis of phosphorylated STAT1a, Jak1, and Jak2, the blots
were stripped and reprobed with antibodies against STAT1a, Jak1, or Jak2,
respectively, as described above.
Measurement of cAMP amount Tumor cells were plated at 4104
cells per well in 24-well plates, adhered for 18 h, then serum and growth
factor deprived for 24 h, and preincubated with several reagents for 10min,
then incubated with histamine in the presence or absence of IFN-g for
10min The cells were lyzed and cAMP amount in the lysate was
measured with an ELISA kit (Amersham). The sensitivity of the assay was
12 fmol per assay well.
Assays of protein kinase A (PKA) Tumor cells were incubated with
histamine for 10min as described above, and were lyzed and the lysate
was assayed for the activity of PKA using an ELISA kit (Medical
and Biological Laboratories, Nagoya, Japan) by examining the
phosphorylation of plate-bound peptide substrate in the presence or
absence of 2 mM cAMP for 10min at room temperature. The plates
were sequentially incubated with biotinylated antibody against the
phosphorylated substrate, peroxidase-conjugated streptavidin, o-
phenylenediamine, then the reaction was stopped, and optical density
(OD) at 492 nm was read. The net OD was calculated by subtracting the
OD in the presence of speci¢c PKA inhibitor KT-5720 (Calbiochem) 1
mM from the total OD. The PKA activity was expressed as an activity
ratio, which is de¢ned as the net OD in the absence of exogenous cAMP
divided by the net OD in the presence of cAMP.
Measurement of histamine release Tumor cells (4104 per well) were
cultured in the presence or absence of IFN-g 10 ng per ml in 1ml of serum
and growth factor-free medium in 24-well plates for 24 h. The supernatant
histamine amount was measured by ELISA (Cosmo Bio, Tokyo, Japan).
The sensitivity of the assay was 0.5 nM.
RESULTS
The level of histamine released from SCC and
melanoma The SCC and melanoma cells released histamine at
varying degrees, and the release was reduced by IFN-g (Table I).
The results are consistent with a previous report showing that
IFN-g inhibited the expression of histidine decarboxylase in
melanoma (Heninger et al, 2000).
The presence of H1, H2, H3, and H4 receptors in SCC and
melanoma As examined by reverse transcription^PCR, H1
and H2 receptor mRNA expression was detected in SCC15
(Fig 1), SCC4, SV40-transformed keratinocytes, and melanoma
WM115 (data not shown), whereas only H2 receptor mRNA
was detected in melanomaWM266-4 (Fig 1) and C32 (data not
shown). None of the cell lines expressed H3 or H4 receptor
mRNAs. We then examined if histamine may alter IP-10
production in these cells via H1 or H2 receptors.
The e¡ects of histamine on IFN-c-induced IP-10
secretion In both SCC15 and WM266-4, the constitutive IP-
10 secretion without IFN-g was minimal (58 7 6 pg per ml in
SCC15; 437 3 pg per ml inWM266-4, mean7 SD of triplicate
culture) (Fig 2a). IFN-g 10 ng per ml enhanced the IP-10
secretion in both cell lines (1472 7 143 pg per ml in SCC15;
1203 7 112 pg per ml in WM266-4 in the presence of IFN-g,
respectively). Though exogenous histamine did not alter
constitutive IP-10 secretion, it suppressed the IFN-g-induced IP-
10 secretion; signi¢cant inhibition occurred at 0.1 mM, and
increased in a concentration-dependent manner and maximized
at 10 mM (Fig 2a). The percentage inhibition of the IFN-g-
induced IP-10 secretion by 10 mM histamine was 80.5% in SCC15
and 74.5% in WM266-4, respectively. Histamine similarly
inhibited IP-10 secretion induced by IFN-g 100 ng per ml (data
not shown). The inhibitory e¡ect of histamine was blocked by
H2 receptor antagonist cimetidine but not by H1 receptor
antagonist mepyramine (Fig 2b) or H3 receptor antagonist
thioperamide (data not shown) in both SCC15 and WM266-4.
Mepyramine, cimetidine, or thioperamide neither altered
constitutive nor IFN-g-induced IP-10 secretion in the absence of
exogenous histamine (data not shown). H2 receptor agonist
dimaprit inhibited IFN-g-induced IP-10 secretion in both cells,
whereas it was not altered by the H1 receptor agonist HTMT
(Fig 2b) or H3 receptor agonist imetit (data not shown). Similar
results were obtained in the other SCC or melanoma cell lines
Table I. Histamine release from SCC and melanoma cells
Histamine release (nM)a
Control IFN-g 10 ng/mL
SV40-transformed 15.472.1b 3.57 0.5 (-77)c,d
Keratinocytes
SCC15 28.373.1 9.37 l.l(-67)d
SCC4 19.271.9 5.670.8(-71)d
WM115 25.172.9 4.27 0.6 (-83)d
WM266-4 13.171.9 2.870.5(-78)d
C32 30.174.2 5.170.8 (-83)d
aConditioned media from SCC and melanoma cells were analyzed for hista-
mine.
bMean7SEM(w ¼ 5).
cThe values in parentheses are percentage decrease compared to controls.
dpo0.01 versus controls, by paired t test.
Figure1. Expression of histamine receptor mRNAs in SCC15 and
WM266-4. mRNA expression was analyzed by reverse transcription^
PCR. A size marker is shown in the far right lane. The results shown in
the ¢gure are representative of ¢ve separate experiments. As positive con-
trols, PCR was performed using cDNA from human peripheral blood
leukocytes for H1, H2, and H4 receptors, and glyceraldehyde-3-phos-
phate dehydrogenase, and cDNA from human brain for H3 receptor,
respectively.
HISTAMINE INHIBITS IP-10 PRODUCTION IN SKIN CANCERS 1413VOL. 119, NO. 6 DECEMBER 2002
and SV40-transformed keratinocytes. These results suggest that
histamine may inhibit IFN-g-induced IP-10 secretion via H2
receptors in SCC and melanoma. We then examined if
histamine may suppress IP-10 mRNA expression induced by
IFN-g in these cells.
The e¡ects of histamine on IFN-c-induced IP-10 mRNA
expression Though histamine alone did not alter IP-10
mRNA level in unstimulated SCC15 cells, histamine suppressed
the IFN-g-induced IP-10 mRNA expression by 67% of controls
as determined by competitive reverse transcription^PCR (Fig 3).
The e¡ect of histamine was blocked by cimetidine and not by
mepyramine or thioperamide (data not shown). Similar results
were obtained in the other SCC or melanoma cells (data not
shown). We then examined if histamine may suppress IP-10
promoter activity induced by IFN-g in these cells.
The e¡ects of histamine on IP-10 promoter activity We
transiently transfected human IP-10 promoter-luciferase reporter
constructs into SCC15 cells, and the promoter activity was
assessed by the relative luciferase activities of the cell lysates.
IFN-g 10 ng per ml increased wild-type IP-10 promoter activity
16.7-fold of controls (Fig 4b, uppermost four columns), and
histamine suppressed the response to IFN-g by 86%. The
inhibitory e¡ect of histamine was blocked by cimetidine, but
not by mepyramine or thioperamide (data not shown).
Histamine also suppressed the IFN-g-induced IP-10 promoter
activation in the other SCC or melanoma cells, and the e¡ects
were blocked by cimetidine (data not shown). Thus histamine
may suppress IP-10 promoter induction by IFN-g via H2
receptors in SCC and melanoma.
IP-10 promoter contains two nuclear factor-kB (NF-kB) sites
and the element corresponding to ISRE (Ohmori and Hamilton,
1993; Ohmori et al, 1997; Majumder et al, 1998) (Fig 4a).We thus
examined which of these elements may be responsible for
the inhibition by histamine on the IFN-g-induced IP-10
transcription. The mutation of ISRE completely abrogated the
induction by IFN-g of IP-10 promoter and the suppression by
histamine on the response to IFN-g in SCC15 cells (Fig 4b, the
second four columns), suggesting that ISRE is necessary for IFN-
g-induced promoter activation and may be involved in the
suppression by histamine on the response to IFN-g.When either
NF-kB2 (distal NF-kB site) or NF-kB1 (proximal NF-kB site)
was mutated, the basal promoter activity was reduced, whereas
the fold induction by IFN-g and the suppression by histamine
Figure 2. The e¡ects of histamine on IFN-g-induced IP-10 secretion in a
concentration-dependent manner (a) and the inhibition by H1 or H2 re-
ceptor antagonists on the e¡ects of histamine (b). (a) SCC15 andWM266-
4 cells were preincubated with indicated concentrations of histamine for
10min prior to the addition of 10 ng IFN-g per ml. After 24 h, the culture
supernatants were assayed for IP-10. Values are mean 7 SD of triplicate
cultures. npo 0.05 vs control cultures, by one-way ANOVA with Dunnett’s
multiple comparison test. The data shown in the ¢gure are representative
of ¢ve separate experiments. (b) SCC15 or WM266-4 cells were preincu-
bated for 10min with mepyramine (ME) or cimetidine (CI) (each 10 mM),
then incubated with histamine (HA) 10 mM for 10min prior to the addition
of IFN-g (10 ng per ml). After 24 h, the supernatants were assayed for IP-10.
In some experiments, the cells were incubated with HTMT or dimaprit
(each 10 mM) in place of histamine without antagonists, prior to the addi-
tion of IFN-g.Values are mean7 SEM of ¢ve separate experiments. npo
0.05 vs control cultures, wpo 0.05 vs cultures with IFN-g, and zpo 0.05 vs
cultures with IFN-g plus histamine, by one-way ANOVAwith Sche¡e’s mul-
tiple comparison test.
Figure 3. The e¡ects of histamine on IFN-c-induced IP-10 mRNA
expression in SCC15 cells. (a) SCC15 cells were preincubated with me-
pyramine (ME) or cimetidine (CI) (each 10 mM) for 10min, then incubated
with 10 mM histamine (HA) for 10min prior to the addition of IFN-g (10
ng per ml). After 3 h, RNAwas isolated. (b) The amounts of IP-10 mRNA
determined by competitive reverse transcription^PCR were shown. (c)
Competitive reverse transcription^PCR was performed for cells treated
with IFN-g or IFN-g plus histamine with indicated concentrations of
competitor. The results shown in the ¢gure are representative of ¢ve sepa-
rate experiments.
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on the response to IFN-g were retained. Similar results were
obtained in the other SCC or melanoma cells (data not shown).
Thus the two NF-kB sites may not be involved in the
suppression by histamine on the response to IFN-g. We then
analyzed if histamine may suppress the ISRE-dependent
transcription induced by IFN-g.
The e¡ects of histamine on the IFN-c-induced transcription
from ISRE SCC15 cells were transiently transfected with
plasmids containing three repeats of ISRE linked to the
heterologous minimal SV40 promoter and luciferase reporter,
and were incubated with histamine together with IFN-g. IFN-g
increased the ISRE-dependent transcriptional activity, and
histamine suppressed the response to IFN-g by 86% of controls
(Fig 5, the upper ¢ve columns). The suppressive e¡ect of
histamine was blocked by cimetidine, and not by mepyramine,
indicating that histamine may suppress the IFN-g-induced
transcription from ISRE via H2 receptors in SCC15. Similar
results were obtained in the other SCC or melanoma cells (data
not shown). We then examined if histamine may suppress the
IFN-g-induced transcription factor binding to ISRE.
The e¡ects of histamine on transcription factor binding to
ISRE The nuclear extracts from unstimulated SCC15 cells did
not form a DNA^protein complex with the ISRE probe (Fig 6a,
lane 2; Fig 6b, lanes 1^4). IFN g induced DNA^protein complex
with ISRE (Fig 6a, lane 3), and the antibodies against STAT1a
and 48 kDa ISRE-binding protein (p48) supershifted the IFN-g-
induced complex (Fig 6b, lanes 6 and 7), indicating the presence
of STAT1a and p48 in the complex. The antibody against STAT2
(Fig 6b, lane 8) did not alter the migration of the IFN-g-induced
complex. On the other hand, the IFN-a-induced complex with
ISRE was supershifted by anti-STAT2 antibody (Fig 6b, lanes
9^12), indicating the presence of STAT2 in the IFN-a-induced
complex. The addition of histamine reduced the amount of
IFN-g-induced complex with the ISRE probe, and cimetidine
counteracted the e¡ect of histamine (Fig 6a, lanes 4 and 7),
whereas mepyramine did not (data not shown). Preincubation
with actinomycin D and cycloheximide, inhibitors of new
RNA and protein synthesis, respectively, did not a¡ect the
inhibition by histamine (Fig 6a, lanes 5 and 6). Similar results
were obtained in the other SCC or melanoma cells (data not
shown). These suggest that histamine may suppress IFN-g-
induced STAT1a/p48 binding to ISRE via H2 receptors in SCC
and melanoma cells, independently of new RNA and protein
synthesis.
The e¡ects of histamine on IFN-c-induced tyrosine
phosphorylation of STAT1a, Jak1, and Jak2 Upon IFN-g
binding, cell surface IFN-g receptor dimerizes, which allows
the receptor-associated Jak1 and Jak2 to autophosphorylate on
Figure 4.The e¡ects of histamine on the IFN-c-induced activities of
wild-type or mutated IP-10 promoters. (a) Schematic representation of
human IP-10 promoter. The nucleotide positions are relative to the tran-
scriptional start site. (b) SCC15 cells were transiently transfected with
wild-type (WT) or mutated human IP-10 promoter linked to luciferase re-
porter together with b-galactosidase vector. The cells were preincubated
with or without 10 mM cimetidine (CI) for 10min, then treated with 10
mM histamine for 10min prior to the addition of IFN-g (10 ng per ml).
After 6 h, cells were harvested. The data are mean7 SEM of four separate
experiments.Values on right indicate the fold induction vs basal promoter
activity. npo 0.05 vs control values, wpo 0.05 vs values with IFN-g, and
zpo 0.05 vs values with IFN-g plus histamine, by one-way ANOVA with
Sche¡e’s multiple comparison test.
Figure 5.The e¡ects of histamine on ISRE-dependent transcription
induced by IFN-c. SCC15 cells were transiently transfected with lucifer-
ase reporter plasmids driven by ISRE linked to heterologous SV-40mini-
mal promoter together with b-galactosidase vector. The cells were allowed
to recover for 18 h and preincubated with cimetidine (CI) or mepyramine
(ME) (each 10 mM) for 10min, then incubated with 10 mM histamine (HA)
for 10min prior to the addition of IFN-g (10 ng per ml). After 6 h, cells
were harvested.The results represent mean7 SEM of four separate experi-
ments. Values on right indicate the fold induction vs basal activity. npo
0.05 vs control values, wpo 0.05 vs values with IFN-g, and zpo 0.05 vs
values with IFN-g plus histamine, by one-way ANOVAwith Sche¡e’s multi-
ple comparison test.
Figure 6. The e¡ect of histamine on IFN-c-induced transcription
factor binding to ISRE. SCC15 cells were preincubated with or without
5 mg actinomycin D per ml (ActD), 20 mg cycloheximide per ml (CHX), or
10 mM cimetidine (CI) for 10min, then incubated with 10 mM histamine
(HA) for 10min prior to the addition of IFN-g (10 ng per ml). After
30min, nuclear extracts were prepared. In some experiments, the cells were
incubated with IFN-a (500 U per ml). The nuclear extracts were incubated
with 32P-labeled oligonucleotides containing ISRE. In supershift assays (b),
antibodies against transcription factors were incubated for 30min before
the addition of the probe. The arrow in (a) indicates the IFN-g-induced
complex, and the arrows in (b) indicate the supershifted complexes. The
results shown in the ¢gure are representative of four separate experiments.
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tyrosine. The activated Jak1 and Jak2 tyrosine phosphorylate the
intracellular domains of IFN-g receptors, which induces the
recruitment of STAT1a to the receptors. The receptor-associated
STAT1a is then tyrosine phosphorylated by the activated Jak1
and Jak2, which induces STAT1a dimerization and association
with p48. The activated STAT1a homodimers/p48 complex
translocates to the nucleus and binds to ISRE on the IP-10 gene
(Bluyssen et al, 1995; Delgado and Ganea, 2000). Thus the
suppression by histamine on IFN-g-induced STAT1a activation
indicates that histamine may suppress the IFN-g-induced
tyrosine phosphorylation of STAT1a, Jak1, or Jak2.We examined
the e¡ects of histamine on the tyrosine phosphorylation status of
these molecules. IFN-g induced tyrosine phosphorylation of
STAT1a, Jak1, and Jak2 in SCC15 (Fig 7, upper panel, lane 2),
and that was suppressed by histamine (Fig 7, upper panel, lane
3). The suppression by histamine was counteracted by cimetidine
(Fig 7, upper panel, lane 4) but not by mepyramine (data not
shown). The total amount of STAT1, Jak1, or Jak2 in the
immunoprecipitates was not altered (Fig 7, lower panel). Similar
results were obtained in the other SCC or melanoma cells (data
not shown). Thus histamine may suppress IFN-g-induced
tyrosine phosphorylation of Jak1, Jak2, and STAT1a via H2
receptors in SCC and melanoma.
The histamine-induced signaling pathways responsible for
the inhibition of IFN-c-induced STAT1a activation and
IP-10 production H1 receptor couples to phospholipase C
via guanine nucleotide-binding protein (G-protein), Gq/11 and
generates inositol 1,4,5-triphosphate and diacylglycerol, the
former inducing intracellular Ca2þ mobilization and the latter
activating protein kinase C (Tilly et al, 1990; Bakker et al, 2001).
H2 receptor was classically thought to couple to adenylate
cyclase via G-protein, Gs, and to generate cAMP signal and
consequently activate cAMP-dependent protein kinase, PKA
(Del Valle and Gantz, 1997). Recent studies, however, indicate
that H2 receptor also couples to phospholipase C/protein kinase
C pathway via G-proteins di¡erent from Gs (Leurs et al, 1995; Del
Valle and Gantz, 1997). We thus aimed to de¢ne the histamine-
mediated signaling pathway responsible for the inhibition on
IFN-g-induced STAT1a activation and IP-10 synthesis. Adenylate
cyclase inhibitor SQ22536 and PKA inhibitor H-89 counteracted
the suppression by histamine on IFN-g-induced IP-10 secretion
(Fig 8a), mRNA expression (Fig 8c), and promoter activation
(Fig 8b) in SCC15, whereas these were not counteracted by
phospholipase C inhibitor U73122 and protein kinase C
inhibitor calphostin C. Similar results were obtained in the
other SCC and melanoma cells (data not shown). These suggest
that cAMP/PKA signaling pathway may be responsible for the
suppression by histamine on IFN-g-induced IP-10 synthesis. This
is supported by the fact that cell-permeable cAMP analog
dibutyryl cAMP and adenylate cyclase stimulator forskolin
inhibited IFN-g-induced IP-10 synthesis (Fig 8). We then
analyzed if cAMP/PKA pathway may also be involved in the
histamine-induced suppression of STAT1a activation. SQ22536
and H-89 counteracted the suppression by histamine on ISRE-
dependent transcription induced by IFN-g in SCC15 cells,
whereas that was not counteracted by U73122 and calphostin C
(Fig 9a). SQ22536 and H-89 did counteract (Fig 9b,c, lanes 4 and
5), but U73122 and calphostin C (Fig 9b,c, lanes 6 and 7) did not
counteract the suppression by histamine on transcription factor
binding to ISRE (Fig 9b) and on tyrosine phosphorylation of
STAT1a, Jak1, and Jak2 (Fig 9c, upper panel) induced by IFN-g.
Similar results were obtained in the other SCC and melanoma
cells (data not shown). These results suggest that the cAMP/PKA
pathway may be responsible for the inhibition by histamine on
IFN-g-induced STAT1a activation. This is also supported by the
fact that dibutyryl cAMP and forskolin inhibited IFN-g-induced
STAT1a activation (Fig 9).
Histamine-induced cAMP signal and PKA activation We
then examined if histamine may generate cAMP signal and
activate PKA in SCC15. Incubation of SCC15 with histamine
alone for 10min increased intracellular cAMP level 12-fold and
enhanced PKA activity in parallel (Fig 10a,b). IFN-g did not
alter cAMP level and PKA activity either in the presence or
absence of histamine. Cimetidine counteracted the histamine-
induced increases of cAMP and PKA activity but mepyramine
did not. Similar results were obtained in the other SCC and
melanoma cells (data not shown). These results suggest that
histamine may stimulate adenylate cyclase via H2 receptors and
generate cAMP and consequently activate PKA in SCC and
melanoma.
Figure 7.The e¡ects of histamine on STAT1a(a), Jak1 (b), or Jak2 (c)
tyrosine phosphorylation induced by IFN-c. SCC15 cells were prein-
cubated with or without 10 mm cimetidine (CI) for 10min, then incubated
with 10 mM histamine (HA) for 10min prior to the addition of IFN-g (10
ng per ml). After 10min, cell lysates were immunoprecipitated with anti-
STAT1a, Jak1, or Jak2 antibodies followed by immunoblotting with anti-
phosphotyrosine antibody (upper panel). The blots were also stripped and
reprobed with anti-STAT1a, Jak1, or Jak2 antibodies, respectively (lower
panel). The results shown in the ¢gure are representative of ¢ve separate
experiments.
Figure 8. The inhibition by several signal inhibitors on histamine-
mediated suppression of IP-10 secretion (a), promoter activity (b),
and mRNA expression (c) induced by IFN-c. (a,c) SCC15 cells were
preincubated with 200 mM SQ22536, 1 mM H-89, 1 mM U73122, or 1 mM cal-
phostin C (CalC) for 10min, then incubated with 10 mM histamine (HA)
for 10min prior to the addition of IFN-g (10 ng per ml). IP-10 secretion
was analyzed after 24 h, whereas RNAwas extracted after 3 h. In some ex-
periments, 1 mm dibutyryl cAMP (Bt2cAMP) or 100 mM forskolin (FSK)
was added in place of histamine prior to the addition of IFN-. (b) SCC15
cells were transiently transfected with human IP-10 promoter linked to lu-
ciferase reporter plasmid, and incubated as above. After 6 h, luciferase activ-
ities of the cell lysates were analyzed and were normalized for b-
galactosidase activities. (a,b) Values are mean 7 SEM of ¢ve separate ex-
periments. npo 0.05 vs control values, wpo 0.05 vs values with IFN-, and
zpo 0.05 vs values with IFN-g plus histamine, by one-way anova with
Sche¡e’s multiple comparison test. The results shown in (c) are representa-
tive of ¢ve separate experiments.
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DISCUSSION
This study demonstrated that histamine inhibited IFN-g-induced
IP-10 production in SCC and melanoma. Histamine may interact
with H2 receptor and trigger cAMP signal and thus activate PKA
in these cells. The activated PKA may inhibit the IFN-g-induced
activation of Jak1,2/STAT1a signaling pathway, and consequently
inhibit IP-10 transcription. A variety of studies reported the
cAMP-mediated inhibition of STAT1a (David et al, 1996a; Ivash-
kiv et al, 1996; Sengupta et al, 1996; Catalan et al, 1997; Lee and
Rikihisa, 1998; Meloche et al, 2000; Rocchi et al, 2000). It is also
reported that cAMP-elevating agents inhibited IFN-g-responsive
gene expression; vasoactive intestinal polypeptide and pituitary
adenylate cyclase-activating polypeptide inhibited IFN-g-in-
duced STAT1 binding to the IFN-g-activated site on the promo-
ter of IFN regulatory factor-1 via cAMP, and inhibited the
expression of this gene in murine macrophages (Delgado and
Ganea, 2000). Multiple mechanisms have been supposed for the
cAMP-mediated inhibition of STAT1 activation: (i) PKA may
suppress the synthesis of STAT1 (Ivashkiv et al, 1996), or (ii) of
Jak1 or Jak2 (Meloche et al, 2000); (iii) PKA may phosphorylate
Jak1 or Jak2 on serine residues, which reduces their tyrosine ki-
nase activities (Meloche et al, 2000), (iv) PKA may stimulate the
activity of protein tyrosine phosphatase, which inactivates Jak1 or
Jak2 (Catalan et al, 1997; Lee and Rikihisa, 1998; Meloche et al,
2000; Rocchi et al, 2000). Among these, the ¢rst and second me-
chanisms are rather unlikely as the amount of Jak1, Jak2, or
STAT1was not altered by histamine. The third mechanism is as-
sumed for another Jak family kinase, Tyk2; however, it has been
reported that Jak1 and Jak2 do not contain the PKA recognition
site (Meloche et al, 2000). The fourth mechanism is rather likely as
PKA is known to phosphorylate tyrosine phosphatases SHPTP2
and SHPTP1 on serine, which enhances their tyrosine phospha-
tase activity (Bouchard et al, 1994; Catalan et al, 1997; Rocchi et al,
2000). Further studies should elucidate if histamine may activate
SHPTP1, SHPTP2, or another protein tyrosine phosphatase that
can inactivate Jak1 or Jak2. Another possible mechanism is that
activated PKA may serine phosphorylate IFN-g receptor, which
may prevent its dimerization and the activation of Jak1/Jak2 asso-
ciated with the receptor. As PKA constitutively associates with
IFN-a/b receptors (David et al, 1996a), its association with IFN-g
receptor before and after histamine incubation should also be
examined in further studies.
Recently, results that contrast with ours have been reported:
histamine enhanced IFN-g-induced tyrosine phosphorylation of
STAT1 in murine splenocytes (Osna et al, 2001a) or anti-CD3 or
phorbol myristate acetate/ionomycin-induced Jak/STAT pathway
in murine Th2 D10.G4.1 cells (Elliot et al, 2001; Osna et al,
2001b). This discrepancy may be possibly because histamine may
act on these murine cells and trigger certain signals other than
cAMP, such as activation of mitogen-activated protein kinases
(Robinson and Dickenson, 2001), which may promote the activ-
ity of STAT1 (David et al, 1995). Alternatively, cAMP induced
by histamine may stimulate tyrosine phosphatase SHPTP2 to
dephosphorylate inhibitory phosphotyrosine residues of Jak1
or Jak2 in murine cells as SHPTP2 either inhibits or enhances
Jak activity dependently on cell types (David et al, 1996b; Yin
et al, 1997).
H1 receptor mRNAwas detected in SCC and melanoma cells
except forWM266-4 and C32. It is also reported that the stimu-
lation of H1 receptor, which is linked to Gq/11, activates NF-kB
via phospholipase C/protein kinase C pathway or via free Gbg
Figure 9. The inhibition by several signal inhibitors on the suppres-
sion by histamine on ISRE-dependent transcription (a), transcrip-
tion factor binding to ISRE (b), and STAT1a, Jak1, or Jak2 tyrosine
phosphorylation (c) induced by IFN-c. (a) SCC15 cells were transiently
transfected with luciferase reporter vector driven by ISRE linked to mini-
mal SV40 promoter. Cells were preincubated with 200 mM SQ22536, 1 mM
H-89, 1 mMU73122, or 1 mM calphostin C (CalC) for 10min, then incubated
with 10 mM histamine (HA) for 10min prior to the addition of IFN-g (10
ng per ml). After 6 h, luciferase activities of the cell lysates were analyzed
and normalized for b-galactosidase activities. In some experiments, 1 mm
dibutyryl cAMP (Bt2cAMP) or 100 mM forskolin (FSK) was added in place
of histamine prior to the addition of IFN-g. The data are mean7 SEM of
¢ve separate experiments. npo 0.05 vs control values with medium alone,
wpo 0.05 vs values with IFN-g alone, and zpo 0.05 vs values with IFN-g
plus histamine, by one-way ANOVAwith Sche¡e’s multiple comparison test.
(b,c) SCC15 cells were preincubated and incubated as above. After 30min,
nuclear extracts were obtained and analyzed for electrophoretic mobility
shift assay using ISRE probe (b). Cell lysates were obtained after 10min,
and immunoprecipitated with anti-STAT1a, Jak1, or Jak2 antibodies fol-
lowed by immunoblotting with anti-phosphotyrosine antibody (c, upper
panel). The blots were also stripped and reprobed with anti-STAT1a, Jak1,
or Jak2 antibodies, respectively (c, lower panel). The results shown in the ¢g-
ure are representative of ¢ve separate experiments.
Figure10. Histamine-induced increase of intracellular cAMP level
(a) and activation of PKA (b). SCC15 cells were preincubated with me-
pyramine (ME) or cimetidine (CI) (each 10 mM) for 10min, then incubated
with 10 mM histamine (HA) in the presence or absence of IFN-g (10 ng per
ml). After 10min, intracellular cAMP level and PKA activity were ana-
lyzed. The results are shown as mean7 SEM of ¢ve separate experiments.
npo 0.05 vs control values, and wpo 0.05 vs values with IFN-g plus hista-
mine, by one-way ANOVAwith Sche¡e’s multiple comparison test.
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subunits dissociated from Gaq/11bg heterotrimer (Lallena et al,
1999; Xie et al, 2000; Bakker et al, 2001). IP-10 promoter contains
two NF-kB sites, and the NF-kB activation by tumor necrosis
factor-a synergistically enhances the ISRE-mediated IP-10 tran-
scription by IFN-g (Ohmori et al, 1997). Histamine and the H1
receptor agonist HTMT, however, did not increase the IFN-g-in-
duced IP-10 synthesis in SCC and melanoma cells containing H1
receptors. It is thus unlikely that histamine may promote IP-10
production via NF-kB in these cells. This is possibly because IP-
10 promoter activity in SCC and melanoma may be predomi-
nantly dependent on STAT1a and the contribution of NF-kB
may be much smaller. Alternatively, the magnitude of H1 recep-
tor stimulation by histamine may be insu⁄cient for the NF-kB
activation, or protein kinase C or Gbg may not be functionally
linked to NF-kB activation in these cells.
The levels of histamine constitutively released by SCC or mel-
anoma were 0.01^0.03 mM, and the release was reduced by IFN-g
to 0.002^0.01 mM (Table I). These endogenous histamine levels
were below the threshold (0.1 mM) for the suppression of IFN-g-
induced IP-10 secretion.Thus the amounts of histamine produced
by SCC or melanoma may be insu⁄cient for the signi¢cant
autocrine activity to inhibit IP-10 induction by IFN-g The IP-10
induction, however, may be inhibited by much larger amounts of
histamine derived from peritumoral mast cells in vivo. As turn-
over rate of histamine is low in mast cells (Wingren et al, 1983),
mast cells have high levels of histamine with low levels of histi-
dine decarboxylase activity. Mast cells may possibly act as a stable
storage pool of histamine for tumor cells in vivo and provide a
su⁄cient amount of histamine to inhibit IP-10 induction by
IFN-g.
A recent study reported that histamine enhances the growth of
melanoma via an H2 receptor, whereas it inhibits its growth via
an H1 receptor (Falus et al, 2001). Neither exogenous histamine
nor H2 agonist dimaprit, however, increased 3H-thymidine up-
take of SCC or melanoma cells used in this study (data not
shown). Besides, H1 agonist HTMTdid not inhibit 3H-thymidine
uptake of these cells (data not shown). Thus histamine did not
appear to alter the proliferation of these cells. As growth factors
for tumor cells, especially for melanoma, di¡er dependently on
the cell lines and clones (Lazar-Molnar et al, 2000), histamine
may not act as a growth factor for SCC or melanoma cell lines
used in this study.
Although we and others (Uotila, 1996) have shown the inhibi-
tory e¡ects of histamine on anti-tumor immunity, some studies
show the favorable e¡ects of histamine; histamine inhibits the
generation of reactive oxygen species in macrophages and thus
protects natural killer cells or T cells from apoptosis by reactive
oxygen stress (Hansson et al, 1999). Histamine was thus success-
fully introduced into the treatment of patients with melanoma
in combination with IL-2 (Agarwala et al, 2002; Schadendorf
et al, 2002). Possibly the e¡ects of histamine on anti-tumor
immune responses are complicated and may depend on the
experimental systems used, e.g., coculture of natural killer
cells and macrophages or natural killer cells alone. As this
study examined the action of histamine on tumor cells alone,
future studies should use the coculture of tumor cells and im-
munocompetent cells.
Our results indicate that histamine in the vicinity of tumor
cells may suppress the IFN-g^induced IP-10 production in vivo.
The inhibition of IP-10 synthesis by histamine may lead to the
suppression of the host anti-tumor immune responses and also
indirectly sustain the tumor angiogenesis. It is also indicated that
histamine may suppress the other e¡ects of IFN-g on tumor cells,
suchas apoptosis induction (Chin etal,1997),bysuppressingSTAT1a
activation.This possibility should be investigated further. Our re-
sults also suggest that H2 receptor antagonist cimetidine may be
useful for the treatment of skin tumors with high peritumoral
levels of histamine. Cimetidine may in vivo counteract the sup-
pression by histamine on the e¡ects of IFN-g. The combination
of cimetidine with IFN-g may thus enhance the therapeutic
e⁄cacy of IFN-g.
This work was supported in part by an aid from KANAEMedical Research Founda-
tion.
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